Prostate Cancer Clinical Trial
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Summary
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standard-of-care arm).
Lorigerlimab+docetaxel or docetaxel will be administered intravenously (IV) in clinic on Day 1 of each 3-week cycle. Prednisone will be administered orally twice daily. Lorigerlimab will be administered for up to 35 cycles. Docetaxel and prednisone will be administered up to 10 cycles until treatment discontinuation criteria are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) blood tests. Participants will be asked to complete questionnaires about their health and well-being. Routine examinations and blood tests will be performed and evaluated by the study doctor.
Participants who have disease progression standard-of-care arm have the option of continuing on the study to receive lorigerlimab monotherapy.
Eligibility Criteria
Inclusion Criteria:
Metastatic castration-resistant adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
Participants must have ≥ 1 metastatic (measurable or non-measurable per PCWG3) lesion.
Participant has prostate cancer progression at study entry based on PCWG3 criteria.
Participant shows evidence of disease progression after receiving at least 1 prior androgen receptor axis-targeted therapy (ARAT) regimen (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide).
Patients with known history of documented breast cancer gene (BRCA) mutation (germline or somatic) must have received an approved poly ADP ribose polymerase (PARP) inhibitor regimen.
Participants must have adequate performance status, life expectancy and laboratory values.
Exclusion Criteria:
Any condition preventing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
Received prior chemotherapy for mCRPC or checkpoint inhibitors for prostate cancer.
Current active or chronic infections.
Any clinically significant heart, lung, or gastrointestinal disorders.
Allergy to any of the study treatments or components of the study treatments.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Miami Florida, 33135, United States More Info
Principal Investigator
Orlando Florida, 32806, United States More Info
Principal Investigator
Boston Massachusetts, 02215, United States More Info
Principal Investigator
Boston Massachusetts, 02215, United States More Info
Principal Investigator
Grand Island Nebraska, 68803, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
West Valley City Utah, 84119, United States More Info
Principal Investigator
Charlottesville Virginia, 22903, United States More Info
Principal Investigator
North Melbourne , , Australia More Info
Principal Investigator
Brussel , , Belgium More Info
Principal Investigator
Quimper , , France More Info
Principal Investigator
Tbilisi , , Georgia More Info
Principal Investigator
Tbilisi , , Georgia More Info
Principal Investigator
Tbilisi , , Georgia More Info
Principal Investigator
Otwock , , Poland More Info
Principal Investigator
Warsaw , , Poland More Info
Principal Investigator
Rio Piedras , , Puerto Rico More Info
Principal Investigator
Madrid , , Spain More Info
Principal Investigator
Sevilla , , Spain More Info
Principal Investigator
Valencia , , Spain More Info
Principal Investigator
How clear is this clinincal trial information?